Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia

Oncotarget

Volumn 7, Issue 22, 2016, Pages 32846-32853

  Podhorecka, Monika ^a   Halicka, Dorota ^b   Szymczyk, Agnieszka ^a   Macheta, Arkadiusz ^a   Chocholska, Sylwia ^a   Hus, Marek ^a   Darzynkiewicz, Zbigniew ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

CD38; CLL; mTOR; RDW; ZAP 70

Indexed keywords

BIOLOGICAL MARKER; CD38 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE ZAP 70; SOMATOMEDIN C; ANTINEOPLASTIC AGENT; IGF1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; AGING; ANTIGEN EXPRESSION; ARTICLE; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE DISTRIBUTION WIDTH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; TIME TO TREATMENT; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BLOOD; ERYTHROCYTE; KAPLAN MEIER METHOD; MEAN CORPUSCULAR VOLUME; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ERYTHROCYTE INDICES; ERYTHROCYTES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84973558748     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9055     Document Type: Article

References (45)

1. Calligaris-Cappio F, Hamblin TJ. B-Cell Chronic Lymphocytic leukemia: A Bird of a Different Feather. J Clin Oncol. 1999; 17:399-408.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005; 352:804-815.
3. Hamblin TJ, Oscier DG. Chronic lymphocytic leukemia: the nature of the leukemic cells. Blood Rev. 1997; 11:119-122.
4. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002; 99:15524-15529.
5. Burger1 JA, Nicholas Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013; 34:592-601.
6. Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. Entering the Era of Targeted for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician. J Clin Oncol. 2014; 32:3039-3047.
7. Stilgenbauer S. Chromic lymphocytic leukemia: genetics for predicting outcome. Hematology. 2006; 2:185-190.
8. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E, Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348:1764-1775.
9. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94:1848-1854.
10. Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood. 1997; 89:4153-4160.
11. Weng CL, Wang CH, Chen IC, Hsiao KY, Chang KP, Wu SY, Shih HM. Red cell distribution width is an independent predictor of mortality in necrotizing fasciitis. Am J Emerg Med. 2014; 32:1259-62.
12. Braun E, Domany E, Kenig Y, Mazor Y, Makhoul BF, Azzam ZS. Elevated red cell distribution width predicts poor outcome in young patients with community acquired pneumonia. Crit Care. 2011; 15:R194.
13. Ku NS, Kim HW, Oh HJ, Kim YC, Kim MH, Song JE, Oh DH, Ahn JY, Kim SB, Jeong SJ, Han SH, Kim CO, Song YG, et al. Red blood cell distribution width is an independent predictor of mortality in patients with gramnegative bacteremia. Shock. 2012; 38:123-127.
14. Jo YH, Kim K, Lee JH, Kang C, Kim T, Park HM, Kang KW, Kim J, Rhee JE. Red cell distribution is a prognostic factor in severe sepsis and septic shock. Am J Emerg Med. 2013; 31:545-548.
15. Tseliou E, Terrovitis JV, Kaldara EE, Ntalianis AS, Repasos E, Katsaros L, Margari ZJ, Matsouka C, Toumanidis S, Nanas SN, Nanas JN. Red blood cell distribution width is a significant prognostic marker in advanced heart failure, independent of hemoglobin levels. Hellenic J Cardiol. 2014; 55: 457-461.
16. M. Tonelli, F. Sacks, M. Arnold, L. Moye, B. Davis, Pfeffr M. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation. 2008; 117:163-168.
17. Arbel Y, Weitzman D, Raz R, Steinvil A, Zeltser D, Berliner S, Chodick G, Shalev V. Red blood cell distribution width and the risk of cardiovascular morbidity and allcause mortality. A population-based study. Thromb Haemost. 2014; 111: 300-307.
18. Oh HJ, Park JT, Kim JK, Yoo DE, Kim SJ, Han SH, Kang SW, Choi KH, Yoo TH. Red blood cell distribution width is an independent predictor of mortality in acute kidney injury patients treated with continuous renal replacement therapy. Nephrol Dial Transplant. 2012; 27:589-594.
19. Solak Y, Yilmaz MI, Saglam M, Caglar K, Verim S, Unal HU, Gok M, Demirkaya E, Gaipov A, Kayrak M, Cetinkaya H, Eyileten T, Turk S, et al. Red cell distribution width is independently related to endothelial dysfunction in patients with chronic kidney disease. Am J Med Sci. 2014; 347: 118-124.
20. Lee H, Kong SY, Sohn JY, Shim H, Youn HS, Lee S, Kim HJ, Eom HS. Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma. Biomed Res Int. 2014; 2014:145619.
21. Patel KV, Ferruci L, Ershler WB, Longo DL, Guralnik JM. Red cell distribution width and the risk of death in middleaged and older adults. Arch Intern Med. 2009; 169:515-523.
22. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB, CHARM Investigators. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol. 2007; 50:40-47.
23. Allen LA, Felker GM, Mehra MR, Chiong JR, Dunlap SH, Ghali JK, Lenihan DJ, Oren RM, Wagoner LE, Schwartz TA, Adams KF Jr. Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J Card Fail. 2010; 16:230-238.
24. Akin F, Köse N, Ayça B, Katkat F, Duran M, Uysal OK, Arinc H. Relation between red cell distribution width and severity of coronary artery disease in patients with acute myocardial infarction. Angiology. 2013; 64:592-596.
25. Braun E, Kheir J, Mashiach T, Naffaa M, Azzam ZS. Is elevated red cell distribution width a prognostic predictor in adult patients with community acquired pneumonia? BMC Infect Dis. 2014; 14:129.
26. Braun E, Domany E, Kenig Y, Mazor Y, Makhoul BF, Azzam ZS. Elevated red cell distribution width predicts poor outcome in young patients with community acquired pneumonia. Crit Care. 2011; 15:R194.
27. Seretis C, Seretis F, Lagoudianakis E, Gemenetzis G, Salemis NS. Is red cell distribution width a novel biomarker of breast cancer activity? Data from a pilot study," J Clin Med Res, 2013; 5:121-126.
28. Warwick R, N. Mediratta N, Shackcloth M, Shaw M, McShane J, Poullis M. Preoperative red cell distribution width in patients undergoing pulmonary resections for nonsmall-cell lung cancer Eur J Cardiothorac Surgvol. 2014; 45:108-113.
29. Koma Y, Onishi A, Matsuoka H, Oda N, Yokota N, Matsumoto Y, Koyama M, Okada N, Nakashima N, Masuya D, Yoshimatsu H, Suzuki Y. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. PLoS ONE. 2013; 8:e80240.
30. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS Clinical staging of chronic lymphocyticleukemia. Blood. 1975; 46:219-234.
31. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981; 48:196-206.
32. Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. 2013; 88:803-816.
33. Gribben JG. Molecular profiling in CLL. Hematology Am Soc Hematol Educ Program. 2008; 1:444-449.
34. Halicka HD, Zhao H, Li J, Lee Y-S, Hsieh T-C, Wu JM, Darzynkiewicz Z. Potential anti-aging agents suppress the level of constitutive DNA damage-and mTOR-signaling. Aging (Albany). 2012; 4:952-965. doi: 10.18632/ aging.100521.
35. Darzynkiewicz Z, Zhao H, Halicka HD, Li J, Lee Y-S, Hsieh T-C, Wu J. In search of anti-aging modalities: evaluation of mTOR-and ROS/DNA damage-signaling by cytometry. Cytometry A. 2014; 85A:386-599.
36. Kim I, Kim CH, Yim YS, Ahn YS. Autocrine function of erythropoietin in IGF-1-induced erythropoietin biosynthesis. Neuroreport. 2008; 9:1699-1703.
37. Kling PJ, Taing KM, Dvorak B, Woodward SS, Philipps AF. Insulin-like growth factor-I stimulates erythropoiesis when administered enterally. Growth Factors. 2006; 24:218-223.
38. Ratajczak J, Zhang Q, Pertusini E, Wojczyk BS, Wasik MA, Ratajczak MZ. The role of insulin (INS) and insulin-like growth factor-1 (IGF-I) in regulating human erythropoiesis. Studies in vitro under serum-free conditions-comparison to other cytokines and growth factors. Leukemia. 1998; 12:371-381.
39. Anisimov VN, Bartke A.The key role of growth hormoneinsulin-GF-1 signaling in aging and cancer. Crit Rev Oncol Hematol. 2013; 87:201-223.
40. Blagosklonny MV. Rapamycin extends life-and health span because it slows aging. Aging (Albany NY). 2013; 5: 592-598. doi: 10.18632/aging.100591.
41. Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A, Saki N. Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell Mol Life Sci. 2015; 72:2337-2347.
42. Blunt MD, Carter MJ, Larrayoz M, Smith LD, Aguilar-Hernandez M, Cox KL, Tipton T, Reynolds M, Murphy S, Lemm E, Dias S, Duncombe A, Strefford JC, et al. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eμ-TCL1 mouse model. Blood. 2015; 125:4032-4041.
43. Zent CS, Bowen DA, Conte MJ, LaPlant BR, Call TG. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study. Leuk Lymphoma. 2015; 24:1-7.
44. Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111:5446-5456.
45. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87:4990-4997.